Last week we had a great time at the Finnish Organ-on-chip meeting in Tampere 🧫 and fruitful scientific discussions for applications of our microfluidic platform 🔬. Big shoutout to @bodyonchip for bringing the OoC research community together, and thank you to everyone who stopped by for a chat with Sebastien Mosser and Pauliina Junttila at our booth!
About us
High throughput organ-on-chips for preclinical discovery
- Sivusto
-
https://www.akita.bio/
External link for AKITA, by Finnadvance
- Toimiala
- Research
- Yrityksen koko
- 11–50 työntekijää
- Päätoimipaikka
- Oulu
- Tyyppi
- Privately Held
- Perustettu
- 2019
- Erityisosaaminen
Sijainnit
-
Ensisijainen
Get directions
Aapistie 5a
Oulu, 90220, FI
Työntekijät AKITA, by Finnadvance
-
Pontus Stråhlman
Partner at Voima Ventures
-
Jari Moilanen
Chief Operations Executive @ Finnadvance / Overseeing operations
-
Prateek Singh
CEO @ Finnadvance | Protein Science, Nanobiotechnology, all things robotics
-
Tuan Hoang Nguyen
Everything microfluidics, reinvented. Chief Technology Officer @Finnadvance
Päivitykset
-
Our distributor MineBio Life Sciences Limited is bringing our organ-on-chip solutions to asian researchers and developers.
On October 10, 2024, to guide the scientific and rational design of quantitative pharmacology studies in the development of drugs for rare diseases and to effectively apply quantitative pharmacology methods, thereby improving the efficiency of drug development for rare diseases, the Center for Drug Evaluation of the China National Medical Products Administration (CDE) drafted the "Technical Guidelines for Model-Guided Drug Development for Rare Diseases (Draft for Public Comment)." In this draft, it is emphasized that, given the particularity of rare diseases, it is necessary to fully explore and utilize all available data in rare disease drug development. For the first time, the guidelines explicitly propose that data generated from organ-on-chip technology platforms can be used as a source of non-clinical research data in drug development, as mentioned in lines 207 and 208 of the original document.The formal inclusion of technologies such as organoids and organ-on-chips in official written documents marks increased regulatory support in China. With its large population and significant demand for drugs, as well as a promising drug development market, MineBio Life Sciences Limited brings internationally advanced organoid and organ-on-chip solutions to Chinese researchers and developers, while continuously expanding the scope of their applications. Currently, our partner CN Bio AKITA, by Finnadvance InSphero Beonchip offer organoid and organ-on-chip solutions for liver, intestine, lung, blood vessels, skin, blood-brain barrier, and brain. Additionally, some partners Qkine Axol Bioscience Ltd. are suppliers of iPSC-derived cells or inducers/factors, providing solutions for neurological and cardiovascular diseases. We welcome collaborations with global cutting-edge in vitro model solution providers to jointly contribute to the development of rare disease drugs in China 😊 . #organ-on-chip #organoid #iPSC #OOC
-
-
We are excited to participate in the Finnish Organ-on-Chip meeting hosted by the CoEBoC next week! Visit us at our booth and check out our sponsor presentation to learn how we’re advancing in vitro research with our scalable, high-throughput OOC systems 🧫🔬 Shout out to Sebastien Mosser or Pauliina Junttila if you are heading there! #OrganOnChip #OrganOnAChip #PharmaceuticalResearch
-
-
Our Japanese distributor Tokyo Future Style, Inc. presented our platform at #BIOJapan 2024 🇯🇵 We are happy to have a reliable partner for our Japanese customers!
Thank you for visiting our booth at BioJapan2024 and having lots of interest to AKITA - state of the art Organ on Chips technology- by Finnadvance!
-
-
Funding news! €1.6 M EU Funding to advance Organ-on-Chip platform We are excited to announce €1.6 million in new grants from the European Union. This funding will significantly enhance our ongoing mission to transform drug research and development by creating more precise and reliable preclinical models. Through this funding, we will collaborate with a consortium of top-tier partners to drive the development and commercializing of next-generation organ-on-chip platforms. This new capital underscores our leadership in the field and showcases the profound potential of our technology to address critical gaps in medical research. Read more here: https://lnkd.in/dMAqNCC9
-
Our distributor, MineBio Life Sciences Limited, will showcase our platform at the 12th Annual Conference of Drug Toxicology in Shanghai next week.
📣 📣 📣 MineBio will participate in the 12th Annual Conference of Drug Toxicology. The conference will focus on the theme ‘Innovative Toxicology for the Future: Dual-Drive of Quality and Efficiency Leading New Drug Development.’ We will showcase a range of outstanding products, including but not limited to CN Bio Axol Bioscience Ltd. AKITA, by Finnadvance InSphero providing comprehensive and integrated solutions for our Chinese customers. We warmly welcome you to visit and learn more. Date: September 1-3, 2024 Location: Shanghai, China, Everbright Convention & Exhibition Center Booth: C20 #CNBio #AXOL #AKITA #Insphero #MineBio #drugtoxicology #drugdevelopment #organOnAChip #organOnchip #drugdiscovery #pharma #3Dcellculture #iPSC #organoid #NAMs
-
We are thrilled to announce our collaboration with Syngene International Limited, which has validated our AKITA platform for 2X faster Caco-2 assays, reducing the assay readiness time from 21 to just 12 days! This breakthrough promises significant savings in both time and costs for more efficient #preclinical drug testing. #drugdiscovery #pharma #caco2
-
-
Our research and development has been co-funded by the EU for the advancement of the highly scalable AKITA organ-on-chip platform. This initiative aims at de-risking preclinical drug testing by the development of predictive in vitro models 🔬 #organ-on-chip #microfluidics #preclinicaldrugtesting #drugscreening
-
-
🚀 New publication! 🚀 Thrilled to announce that our collaborative research with AstraZeneca has just been published! Our team has developed an iPSC-derived endothelial cell (iEC) model that provides a robust platform for studying venous malformations (VMs) and potentially other vascular diseases with genetic origins. This work underscores the pivotal role of iPSCs in advancing our understanding of vascular disorders and paves the way for personalized medicine. This advancement marks a significant step towards utilizing organ-on-chip technology for modeling and screening platforms, ultimately aiming to discover novel treatments for vascular diseases.
-
-
Simplify complex biological readouts with our high-fidelity impedance spectroscopy and TEER lid. We have made the most compact system for manual and automated use, not only with our platform but with all legacy transwell plates! No workstation or dedicated computer is required. Get your results in our web app AKITA Core on your phone/tablet/PC. And yes, what you see is the whole impedance system for 96, 384, and our plates.